Nacalai to Distribute Techulon Transfection Reagents | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Nacalai USA today said that it has signed an agreement to distribute Techulon's Glycofect Transfection Reagent platform products in Japan.

The reagents are designed to be particularly effective in primary cells of therapeutic interest, said Nacalai. In addition, the San Diego-based firm said that the Glycofect family of reagents has a unique biodegradable composition that provides for efficacious delivery with very low toxicity in key cell types.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.